Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2010

01-07-2010

The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?

Authors: Gregory M. M. Videtic, Kevin L. Stephans

Published in: Current Oncology Reports | Issue 4/2010

Login to get access

Abstract

The standard of care for early-stage lung cancer is surgical resection. Many patients with this diagnosis have comorbidities that preclude oncologic resection. Randomized data show that limited resection is inadequate for local disease control and may negatively impact on survival. Stereotactic body radiotherapy (SBRT) has emerged as a novel radiation modality with significant applications in the inoperable, early-stage lung cancer population. Retrospective and prospective studies published in the past decade have established the feasibility, safety, and efficacy of SBRT in these patients using a variety of dose regimens and technologies. To date, lung SBRT results demonstrate excellent local control with very little acute toxicity, and suggest improved overall survival compared to historical controls of fractionated radiotherapy. Ongoing prospective trials are exploring dose and fractionation schedules in the inoperable population, and are starting to explore the role of SBRT for the operable patient.
Literature
1.
Hansen H: Introduction. In Lung Cancer Therapy Annual, edn 6. Edited by Hansen H. New York: Informa Health Care; 2009:1–6.
2.
3.
Hansen H: Histopathology. In Lung Cancer Therapy Annual, edn 6. Edited by Hansen H. New York: Informa Health Care; 2009:45–56.
4.
Juettner-Smolle FM LJ, Matzi V, Neubock N: Resection in stage I/II non-small cell lung cancer. In Controversies in the Treatment of Lung Cancer. Edited by Karger JH. Basel, Switzerland: 2010:71–77.
5.
Little AG, Rusch VW, Bonner JA, et al.: Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005, 80:2051–2056.CrossRefPubMed
6.
McGarry RC, Song G, des Rosiers P, Timmerman R: Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002, 121:1155–1158.CrossRefPubMed
7.
Jensik RJ, Faber LP, Milloy FJ, Monson DO: Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg 1973, 66:563–572.PubMed
8.
Sibley GS: Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses—a review. Cancer 1998, 82:433–438.CrossRefPubMed
9.
Ginsberg RJ, Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615–622.CrossRefPubMed
10.
Miller JI, Hatcher CR Jr: Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg 1987, 44:340–343.PubMedCrossRef
11.
Shennib H, Bogart J, Herndon JE, et al.: Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg 2005, 129:813–818.CrossRefPubMed
12.
Santos R, Colonias A, Parda D, et al.: Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with stage I non-small-cell lung cancer. Surgery 2003, 134:691–697; discussion 697.CrossRefPubMed
13.
McKenna RJ Jr, Mahtabifard A, Yap J, et al.: Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Ann Thorac Surg 2008, 85:S733–S736.CrossRefPubMed
14.
Allen MS, Darling GE, Pechet TT, et al.: Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006, 81:1013–1019; discussion 1019–1020.CrossRefPubMed
15.
Qiao X, Tullgren O, Lax I, et al.: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003, 41:1–11.CrossRefPubMed
16.
Zierhut D, Bettscheider C, Schubert K, et al.: Radiation therapy of stage I and II non-small cell lung cancer (NSCLC). Lung Cancer 2001, 34(Suppl 3):S39–S43.CrossRefPubMed
17.
Martel MK, Ten Haken RK, Hazuka MB, et al.: Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999, 24:31–37.CrossRefPubMed
18.
Saunders M, Dische S, Barrett A, et al.: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997, 350:161–165.CrossRefPubMed
19.
Perez CA, Pajak TF, Rubin P, et al.: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987, 59:1874–1881.CrossRefPubMed
20.
Song DY, Kavanagh BD, Benedict SH, Schefter T: Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology 2004, 18:1419–1430; discussion 1430–1432.PubMed
21.
Lax I, Blomgren H, Naslund I, Svanstrom R: Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994, 33:677–683.CrossRefPubMed
22.
Nagata Y, Takayama K, Matsuo Y, et al.: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427–1431.CrossRefPubMed
23.
•• Onishi H, Shirato H, Nagata Y, et al.: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94–S100. This is a large series of patients with long-term follow-up treated in Japan with excellent documentation of outcomes, patterns of failure, and dose response. It demonstrates safety of the treatment of central tumors with risk-adapted doses. It also includes a group of medically operable patients who elected SBRT over surgery and have outcomes equivalent to surgical patients at this point.CrossRefPubMed
24.
Uematsu M, Shioda A, Suda A, et al.: Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51:666–670.PubMed
25.
Baumann P, Nyman J, Lax I, et al.: Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787–795.CrossRefPubMed
26.
Guckenberger M, Wulf J, Mueller G, et al.: Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009, 74:47–54.PubMed
27.
• Lagerwaard FJ, Haasbeek CJ, Smit EF, et al.: Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685–692. Along with Guckenberger et al. [26], this is one of several large European series with reported long–term outcomes.PubMed
28.
Wulf J, Baier K, Mueller G, Flentje MP: Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005, 77:83–87.CrossRefPubMed
29.
•• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al.: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677–682. This reports the updated results of the prospective phase II Indiana University [30] series showing long-term outcomes using the United States standard of 60 Gy in three fractions. The initial series demonstrated the safety and efficacy of this regimen for peripheral tumors while cautioning that this dose should not be used for centrally located lesions.PubMed
30.
Timmerman R, McGarry R, Yiannoutsos C, et al.: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833–4839.CrossRefPubMed
31.
Timmerman R, Papiez L, McGarry R, et al.: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946–1955.CrossRefPubMed
32.
Fowler JF, Tome WA, Fenwick JD, Mehta MP: A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004, 60:1241–1256.CrossRefPubMed
33.
• Stephans KL, Djemil T, Reddy CA, et al.: A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol 2009, 4:976–982. This is a retrospective series suggesting similar early rates of local control between 60 Gy in three fractions and 50 Gy in five fractions.CrossRefPubMed
34.
Haasbeek CJ, Lagerwaard FJ, de Jaeger K, et al.: Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 2009, 115:587–594.CrossRefPubMed
35.
Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al.: Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 2010, 116:406–414.CrossRefPubMed
36.
•• Timmerman R, Paulus R, Galvin J, et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070–1076. This is a critical report of the outcomes of stereotactic radiation using the US standard for peripheral lesions (60 Gy in three fractions), demonstrating excellent outcomes and safety in a multi-institutional setting.CrossRefPubMed
37.
• Bradley J: Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2007, 2:S118–S124. This is an excellent review of post-treatment radiographic changes to assist in image interpretation.CrossRefPubMed
38.
Takeda A, Kunieda E, Takeda T, et al.: Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:1057–1065.PubMed
39.
• Henderson MA, Hoopes DJ, Fletcher JW, et al.: A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:789–795. Prospectively collected data on serial PET changes following stereotactic treatment.PubMed
40.
Chang JY, Roth JA: Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin 2007, 17:251–259.CrossRefPubMed
41.
Henderson M, McGarry R, Yiannoutsos C, et al.: Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72:404–409.PubMed
42.
Stephans KL, Djemil T, Reddy CA, et al.: Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009, 4:838–844.CrossRefPubMed
43.
• Dunlap NE, Cai J, Biedermann GB, et al.: Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:796–801. This is an early report of planning parameters to aide in reduction of chest wall toxicity.PubMed
44.
Pettersson N, Nyman J, Johansson KA: Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009, 91:360–368.CrossRefPubMed
45.
Kawase T, Takeda A, Kunieda E, et al.: Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiat Oncol Biol Phys 2009, 74:349–354.PubMed
46.
Hoppe BS, Laser B, Kowalski AV, et al.: Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys 2008, 72:1283–1286.PubMed
47.
Forquer JA, Fakiris AJ, Timmerman RD, et al.: Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009, 93:408–413.CrossRefPubMed
Metadata
Title
The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?
Authors
Gregory M. M. Videtic
Kevin L. Stephans
Publication date
01-07-2010
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 4/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0108-1

Other articles of this Issue 4/2010

Current Oncology Reports 4/2010 Go to the issue

ReviewPaper

Extravasation of Chemotherapy

ReviewPaper

Testicular Cancer: When Less is More

ReviewPaper

New Developments in Targeted Therapy for Soft Tissue Sarcoma

Clinical Trial Report

STEPP for the EGFR Inhibitor–Induced Rash—Definitely a Step in the Right Direction

ReviewPaper

Bladder Cancer: Can We Move Beyond Chemotherapy?

ReviewPaper

Stratifying Osteosarcoma: Minimizing and Maximizing Therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits